The new treatment opportunity may broaden the applicability of cancer vaccines. Through the new vaccine targets — ERVs — treating patients unresponsive to conventional cancer immunotherapy may become possible.
With the elevated focus on this groundbreaking therapeutic concept, Evaxion has initiated preclinical activities with a goal of generating Proof-of-Concept data by the second half of 2024.
Evaxion’s Chief Scientific Officer, Birgitte Rønø, expresses optimism: “With our intensified focus on ERV cancer vaccines, we aim to expedite the development process to deliver treatment solutions to cancer patients who, until now, have been deemed unresponsive to immunotherapy."
"The ERV cancer vaccine targets represent a promising breakthrough that could significantly broaden the horizons of cancer vaccine applicability and marks a significant step forward in our commitment to improving healthcare through innovative and AI-powered approaches.”
